B-cell
epitope sequences from Zika virus (ZIKV) NS1 protein have
been identified using epitope prediction tools. Mapping these sequences
onto the NS1 surface reveals two major conformational epitopes and
a single linear one. Despite an overall average sequence identity
of ca. 55% between the NS1 from ZIKV and the four dengue virus (DENV)
serotypes, epitope sequences were found to be highly conserved. Nevertheless,
nonconserved epitope-flanking residues are responsible for a dramatically
divergent electrostatic surface potential on the epitope regions of
ZIKV and DENV2 serotypes. These findings suggest that strategies for
differential diagnostics on the basis of short linear NS1 sequences
are likely to fail due to immunological cross-reactions. Overall,
results provide the molecular basis of differential discrimination
between Zika and DENVs by NS1 monoclonal antibodies.
Within this study, a novel highthroughput peptide array technology enabled the correlation between the clinical phenotype and the antibody response against linear epitopes of the P. falciparum proteome. Peptides from twelve known vaccine candidates and a bioinformatical selection were screened. Strong reactivities to epitopes derived from known vaccine candidates as well as new immunogenic proteins/epitopes were identified, which may serve as vaccine targets and new biomarkers.
Emergence and re-emergence
of pathogens bearing the risk of becoming
a pandemic threat are on the rise. Increased travel and trade, growing
population density, changes in urbanization, and climate have a critical
impact on infectious disease spread. Currently, the world is confronted
with the emergence of a novel coronavirus SARS-CoV-2, responsible
for yet more than 800 000 deaths globally. Outbreaks caused
by viruses, such as SARS-CoV-2, HIV, Ebola, influenza, and Zika, have
increased over the past decade, underlining the need for a rapid development
of diagnostics and vaccines. Hence, the rational identification of
biomarkers for diagnostic measures on the one hand, and antigenic
targets for vaccine development on the other, are of utmost importance.
Peptide microarrays can display large numbers of putative target proteins
translated into overlapping linear (and cyclic) peptides for a multiplexed,
high-throughput antibody analysis. This enabled for example the identification
of discriminant/diagnostic epitopes in Zika or influenza and mapping
epitope evolution in natural infections versus vaccinations. In this
review, we highlight synthesis platforms that facilitate fast and
flexible generation of high-density peptide microarrays. We further
outline the multifaceted applications of these peptide array platforms
for the development of serological tests and vaccines to quickly encounter
pandemic threats.
Although dengue virus (DENV) affects almost half of the world’s population there are neither preventive treatments nor any long-lasting and protective vaccines available at this time. The complexity of the protective immune response to DENV is still not fully understood. The most advanced vaccine candidates focus specifically on humoral immune responses and the production of virus-neutralizing antibodies. However, results from several recent studies have revealed the protective role of T cells in the immune response to DENV. Hence, in this study, we generated a novel and potent DENV vaccine candidate based on an Orf virus (ORFV, genus Parapoxvirus) vector platform engineered to encode five highly conserved or cross-reactive DENV human leukocyte antigen (HLA)-A*02- or HLA-B*07-restricted epitopes as minigenes (ORFV-DENV). We showed that ORFV-DENV facilitates the in vitro priming of CD8+ T cells from healthy blood donors based on responses to each of the encoded immunogenic peptides. Moreover, we demonstrated that peripheral blood mononuclear cells isolated from clinically confirmed DENV-positive donors stimulated with ORFV-DENV generate cytotoxic T cell responses to at least three of the expressed DENV peptides. Finally, we showed that ORFV-DENV could activate CD8+ T cells isolated from donors who had recovered from Zika virus (ZIKV) infection. ZIKV belongs to the same virus family (Flaviviridae) and has epitope sequences that are homologous to those of DENV. We found that highly conserved HLA-B*07-restricted ZIKV and DENV epitopes induced functional CD8+ T cell responses in PBMCs isolated from confirmed ZIKV-positive donors. In summary, this proof-of-concept study characterizes a promising new ORFV D1701-VrV-based DENV vaccine candidate that induces broad and functional epitope-specific CD8+ T cell responses.
The identification of specific biomarkers for Zika infection and its clinical complications is fundamental to mitigate the infection spread, which has been associated with a broad range of neurological sequelae.
<div>
<div>
<div><p><a></a>In this manuscript we describe the engineering of a biomarker for the diagnosis and prognosis of Zika-associated neurological disease. Although the causal association between congenital Zika virus (ZIKV) infection and neurological manifestations has been well documented in the recent years, biomarkers for proper diagnostic and disease outcome still remain to be defined. Combining high-density peptide array and multivariate analysis, we have identified an ZIKV epitope that is associated to a lack of IgG antibody response in patients with severe neurological symptoms. An engineered chimera was developed to discriminate between mild and severe clinical forms of the disease.</p></div>
</div>
</div>
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.